Reinsurance, Stop-Loss Programs in Managing High-Cost Meds, Per Rick Lassow of Summit Re | AMCP 2023
At the annual AMCP meeting, Summit Re's Vice President of Actuarial & Underwriting, Rick Lassow, FSA, MAAA, led a discussion on managing high-cost medications through reinsurance and stop-loss programs. In this interview with Managed Healthcare Executive Lassow addresses high-cost cell and gene therapies ran through reinsurance and how Medicaid can benefit the most from reinsurance programs.
In this interview with Managed Healthcare Executive, Lassow addressed the situations of high-cost cell and gene therapies ran through reinsurance and how Medicaid can benefit the most from reinsurance programs.
As for gene and cell therapies, they're not much different from other high-investment drugs. He added these types of therapies could be more predictable when it comes to the patient condition because a gene therapy has a defined price take $2.5 to $3 million. Recovery time can be different, too. A burn victim, for example, can be treated differently or have different outcomes because these patients can be in the hospital for a week or more depending on the severity.
Specialty Drugs Dominate Pharmaceutical Frontier in 2025
April 15th 2025In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Read More
340B Program Is Driving Up Costs and Needs Urgent Reform | AMCP Annual 2025
April 7th 2025At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.
Read More
Exploring the Wide World of GLP-1s | AMCP Annual 2025
April 3rd 2025Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.
Read More
